Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis

Gene Therapy

Volumn 11, Issue 2, 2004, Pages 214-223

  Wakimoto, H ^a   Fulci, G ^a   Tyminski, E ^a   Chiocca, E Antonio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Brain tumours; Immune responses; Oncolytic virus; Replication competent virus

Indexed keywords

ALPHA INTERFERON; BETA GALACTOSIDASE; BETA INTERFERON; COMPLEMENT INHIBITOR; CYCLOPHOSPHAMIDE; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN M; INTERLEUKIN 15; INTERLEUKIN 18; MESSENGER RNA; ONCOLYTIC VIRUS; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYSIOLOGY; PRIORITY JOURNAL; RAT; RAT STRAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIROLOGY; VIRUS REPLICATION;

ANIMALS; BRAIN NEOPLASMS; COMPLEMENT INACTIVATOR PROTEINS; CYCLOPHOSPHAMIDE; CYTOKINES; GENE EXPRESSION; GLIOMA; IMMUNOTHERAPY; MODELS, ANIMAL; RATS; RATS, INBRED F344; RATS, NUDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIMPLEXVIRUS; VIRUS REPLICATION;

ANIMALIA; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 0742271990     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302143     Document Type: Article

References (40)

1. Chiocca EA, Smith ER. Oncolytic viruses as novel anticancer agents: turning one scourge against another (In Process Citation). Expert Opin Investig Drugs 2000; 9: 311-327 (MEDLINE record in process).
2. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001; 7: 781-787.
3. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002; 2: 938-950.
4. Markert JM et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial (see comments). Gene Therapy 2000; 7: 867-874.
5. Rampling R et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Therapy 2000; 7: 859-866.
6. Khuri FR et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer (see comments). Nat Med 2000; 6: 879-885.
7. Ichikawa T, Chiocca EA. Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector. Cancer Res 2001; 61: 5336-5339.
8. Wakimoto H, Johnson PR, Knipe DM, Chiocca EA. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Therapy 2003; 10: 983-990.
9. Mitchell BM, Stevens JG. Neuroinvasive properties of herpes simplex virus type 1 glycoprotein variants are controlled by the immune response. J Immunol 1996; 156: 246-255.
10. Fawaz LM, Sharif-Askari E, Menezes J. Up-regulation of NK cytotoxic activity via IL-15 induction by different viruses: a comparative study. J Immunol 1999; 163: 4473-4480.
11. Kodukula P et al. Macrophage control of herpes simplex virus type 1 replication in the peripheral nervous system. J Immunol 1999; 162: 2895-2905.
12. Feduchi E, Alonso MA, Carrasco L. Human gamma interferon and tumor necrosis factor exert a synergistic blockade on the replication of herpes simplex virus. J Virol 1989; 63: 1354-1359.
13. Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 2000; 81: 2341-2364.
14. Ahmad A, Sharif-Askari E, Fawaz L, Menezes J. Innate immune response of the human host to exposure with herpes simplex virus type 1: in vitro control of the virus infection by enhanced natural killer activity via interleukin-15 induction. J Virol 2000; 74: 7196-7203.
15. Fujioka N et al. Interleukin-18 protects mice against acute herpes simplex virus type 1 infection (viruses: a comparative study). J Virol 1999; 73: 2401-2409.
16. Karupiah G et al. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science 1993; 261: 1445-1448.
17. Croen KD. Evidence for antiviral effect of nitric oxide. Inhibition of herpes simplex virus type 1 replication. J Clin Invest 1993; 91: 2446-2452.
18. Leib DA et al. Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. Proc Natl Acad Sci USA 2000; 97: 6097-6101.
19. Ikeda K et al. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol 2000; 74: 4765-4775.
20. Ikeda K et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999; 5: 881-887.
21. Wakimoto H et al. The complement response against an oncolytic virus is species-specific in its activation pathways. Mol Ther 2002; 5: 275-282.
22. Tzeng JJ, Barth RF, Orosz CG, James SM. Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Res 1991; 51: 2373-2378.
23. Geraghty RJ et al. Entry of alpha herpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science 1998; 280: 1618-1620.
24. Kramm CM et al. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 1997; 8: 2057-2068.
25. Advani SJ et al. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Therapy 1998; 5: 160-165.
26. Clarke L, Waxman DJ. Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res 1989; 49: 2344-2350.
27. Matar P, Rozados VR, Gervasoni SI, Scharovsky GO. Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother 2002; 50: 588-596.
28. Leib DA. Counteraction of interferon-induced antiviral responses by herpes simplex viruses. Curr Top Microbiol Immunol 2002; 269: 171-185.
29. Leib DA et al. Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. J Exp Med 1999; 189: 663-672.
30. Zamanian-Daryoush M, Mogensen TH, DiDonato JA, Williams BR. NF-kappaB activation by double-stranded-RNA-activated protein kinase (PKR) is mediated through NF-kappaB-inducing kinase and IkappaB kinase. Mol Cell Biol 2000; 20: 1278-1290.
31. Deb A et al. RNA-dependent protein kinase PKR is required for activation of NF-kappa B by IFN-gamma in a STAT1-independent pathway. J Immunol 2001; 166: 6170-6180.
32. Uetani K et al. Central role of double-stranded RNA-activated protein kinase in microbial induction of nitric oxide synthase. J Immunol 2000; 165: 988-996.
33. Geiger KD et al. Interferon-gamma protects against herpes simplex virus type 1-mediated neuronal death. Virology 1997; 238: 189-197.
34. Halford WP, Schaffer PA. Optimized viral dose and transient immunosuppression enable herpes simplex virus ICP0-null mutants to establish wild-type levels of latency in vivo. J Virol 2000; 74: 5957-5967.
35. Hickman-Davis JM, Lindsey JR, Matalon S. Cyclophosphamide decreases nitrotyrosine formation and inhibits nitric oxide production by alveolar macrophages in mycoplasmosis. Infect Immun 2001; 69: 6401-6410.
36. Wei MX et al. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res 1995; 1: 1171-1177.
37. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988; 62: 196-205.
38. Goldstein DJ, Weller SK. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 1988; 166: 41-51.
39. Goldstein DJ, Weller SK. An ICP6::lacZ insertional mutagen is used to demonstrate that the UL52 gene of herpes simplex virus type 1 is required for virus growth and DNA synthesis. J Virol 1988; 62: 2970-2977.
40. Boviatsis EJ et al. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum Gene Ther 1994; 5: 183-191.